DelveInsight has launched a new report on “Psoriasis – Market Insights, Epidemiology, and Market Forecast-2032”.
DelveInsight’s “Psoriasis – Market Insights, Epidemiology, and Market Forecast-2032″ report deliver an in-depth understanding of the Psoriasis, historical and forecasted epidemiology as well as the Psoriasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Psoriasis Market Report:
- According to a research study, up to 40 % of patients with psoriasis go on to develop PsA, usually within 5-10 years of cutaneous disease onset.
- The study reported the incidence of psoriasis in all ages, with the incidence of the disease varying from 31.4 per 100 000 person-years in eastern Europe (Russia) to 521.1 per 100 000 person-years in western Europe (Germany).
- According to a study, psoriasis Vulgaris represents 90% of cases, psoriasis arthropathic around 4%, followed by guttate type psoriasis (3%), psoriatic erythroderma (1%), and generalized pustular psoriasis (1%) in Japan.
Key benefits of the report:
- Psoriasis market report covers a descriptive overview and comprehensive insight of the Psoriasis Epidemiology and Psoriasis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Psoriasis market report provides insights on the current and emerging therapies.
- Psoriasis market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Psoriasis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Psoriasis market.
Got queries? Click here to know more about Psoriasis Market Landscape.
Psoriasis Overview
Psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by the presence of papules and plaques occurring most commonly on the elbows, knees, scalp, and lower back, but is not limited to these areas.
The key players involved in the Psoriasis market:
- Eli Lilly and Company
- UCB Pharma
- Akros Pharma Inc
- Kadmon Pharmaceuticals
- Dermavant
- And others
The launch of the emerging therapies is expected to significantly impact the Psoriasis treatment scenario in the upcoming years:-
Drug covered
- Mirikizumab
- Bimekizumab
- JTE-451
- KD025
- Tapinarof
- And others.
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Psoriasis Patient Share (%) Overview at a Glance
5. Psoriasis Market Overview at a Glance
6. Psoriasis Disease Background and Overview
7. Psoriasis Epidemiology and Patient Population
8. Country-Specific Patient Population of Psoriasis
9. Psoriasis Current Treatment and Medical Practices
10. Unmet Needs
11. Psoriasis Emerging Therapies
12. Psoriasis Market Outlook
13. Country-Wise Psoriasis Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Psoriasis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/